Greenville, SCNCT06487624Now EnrollingIRB Ready

Advanced Solid Tumor Clinical Trial in Greenville, SC

Access cutting-edge advanced solid tumor treatment through this clinical trial at a research site in Greenville. Study-provided care at no cost to qualified participants.

Sponsored by FBD Biologics Limited

Quick Self-Assessment

See if you qualify for this Greenville location

Preparing your pre-screening questions…

Expert Care in Greenville

Access advanced solid tumor specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced solid tumor treatment provided free

Apply for This Greenville Location

Check if you qualify for this advanced solid tumor clinical trial in Greenville, SC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Greenville

    Convenient for SC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Greenville site if eligible
  4. 4Begin participation

About This Advanced Solid Tumor Study in Greenville

The purpose of this study is to find out whether IV injection of HCB301 is an effective treatment for different types of advanced solid tumors and relapsed and refractory classical Hodgkin lymphomas and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.

Sponsor: FBD Biologics Limited

Who Can Participate

Inclusion Criteria

Able to understand and be willing to sign the ICF.
Male and female subjects of ≥18 years of age.
Histologically/cytologically confirmed, locally advanced solid tumor: subjects confirmed advanced solid tumors who have relapsed or refractory and should have no options for standard or approved therapies known to potentially confer clinical benefit or classical Hodgkin lymphoma, relapsed or refractory to at least 2 prior lines of systemic therapy.
For subjects with advanced solid tumors - must have at least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at baseline.
For subjects with classical Hodgkin lymphoma - must have classical Hodgkin lymphoma that is measurable or assessable for response.
Must have ECOG performance status of 0 to 1 at Screening.
Able to provide tumor tissue samples.
Have a life expectancy of ≥12 weeks.

Exclusion Criteria

With known history of hypersensitivity to any components of HCB301.
Known active or untreated CNS metastases and/or carcinomatous meningitis.
Have undergone a major surgery or radical radiotherapy within 28 days or palliative radiotherapy within 14 days or have used a radioactive drug within 56 days prior to the first dose of HCB301.
Clinically significant cardiovascular condition.
Any previous treatment-related toxicities which have not recovered to ≤ Grade 1 as evaluated by National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 or baseline, except alopecia and anemia.
With known inherited or acquired bleeding disorder or bleeding diathesis. .
Have RBC transfusion within 4 weeks prior to Screening.
With a previously documented diagnosis of hemolytic anemia or Evans Syndrome in the last 3 months.
Any investigational or approved systemic cancer therapy administered within 21 days or 5 half-lives, whichever is shorter, before the first dose of the study drug.
Active use of vitamin K antagonist anticoagulant like warfarin. Use of low molecular weight heparin and factor Xa inhibitors will be permitted on case by case basis. There will be no restriction for daily aspirin ≤ 100 mg/QD.
Have used herbal medication within 14 days prior to the first dose of HCB301.
Have received any treatment targeting the SIRPα-CD47, PD-L1, or TGF-β pathway.
Have other malignancies requiring treatment within 2 years prior to the first dose of HCB301.
An investigational device used within 28 days prior to the first dose of HCB301.
Positive for hepatitis B, active hepatitis C infections, positive for HIV, or known active or latent tuberculosis.
Known to have a history of alcoholism or drug abuse.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Greenville?

Yes, this clinical trial (NCT06487624) has an active research site in Greenville, SC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Solid Tumor Treatment Options in Greenville, SC

If you're searching for advanced solid tumor treatment options in Greenville, SC, this clinical trial (NCT06487624) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Greenville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced solid tumor specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced solid tumor clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Greenville, SC

See all advanced solid tumors clinical trials recruiting in Greenville — not just this study.

Browse Advanced Solid Tumors Trials in Greenville →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAlzheimers Disease TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Greenville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Greenville, SC